Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 859 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Cancer in My Community: Striving to Lead People to Cancer Care... November 22, 2022 Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological... July 16, 2021 WHO’s plans to create a ‘cervical cancer-free future’ April 19, 2021 New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... December 1, 2022 Load more HOT NEWS Thinking outside the box to tackle an aggressive children’s cancer 10 Ways You Can Nurture A More Sustainable Garden Born Blind With 50% Chance Of Survival, 20-Year-Old Musician Defied All... EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate
